Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer
- PMID: 9079743
- DOI: 10.1007/BF00941903
Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer
Abstract
In intravesical therapy for superficial bladder carcinoma urothelial cells may, through the production of cytokines, contribute to the bacillus Calmette-Guerin (BCG)-induced local immunological reaction and associated antitumor efficacy. The aim of this study was to investigate such a role for the neutrophil-attracting cytokine interleukin-8 (IL-8). The appearance of IL-8 in patients urine after BCG therapy was compared with BCG-induced IL-6 and IL-2 and the stability of IL-8 in urine was tested. Compared to IL-6 and IL-2, a rapid induction of IL-8 was observed, occurring after the first BCG instillation. Urinary IL-8 was highly stable, even after 24 h incubation at 37 degrees C. The IL-8 concentration after the first instillation seemed to be associated with subsequent development of an immune response. Consequently, IL-8 seems an attractive candidate for investigation of its prognostic value for a clinical response to BCG therapy.
Similar articles
-
Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.J Urol. 2000 Dec;164(6):2129-33. J Urol. 2000. PMID: 11061941
-
Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.J Urol. 1986 Oct;136(4):970-4. doi: 10.1016/s0022-5347(17)45142-1. J Urol. 1986. PMID: 3489840
-
Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.J Urol. 1996 Feb;155(2):477-82. J Urol. 1996. PMID: 8558640 Clinical Trial.
-
Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview.Urol Int. 1990;45(3):129-36. doi: 10.1159/000281694. Urol Int. 1990. PMID: 2190404 Review.
-
Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature.Eur Urol. 2003 Apr;43(4):351-60; discussion 360-1. doi: 10.1016/s0302-2838(03)00048-4. Eur Urol. 2003. PMID: 12667715 Review.
Cited by
-
Immunotherapeutic strategies for high-risk bladder cancer.Semin Oncol. 2007 Apr;34(2):165-72. doi: 10.1053/j.seminoncol.2006.12.004. Semin Oncol. 2007. PMID: 17382800 Free PMC article. Review.
-
First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin.Eur Urol. 2022 Dec;82(6):602-610. doi: 10.1016/j.eururo.2022.08.004. Epub 2022 Aug 23. Eur Urol. 2022. PMID: 36008193 Free PMC article.
-
Bacillus Calmette Guérin in bladder cancer: is more immune stimulation better?Transl Androl Urol. 2019 Dec;8(Suppl 5):S517-S520. doi: 10.21037/tau.2019.12.23. Transl Androl Urol. 2019. PMID: 32042636 Free PMC article. No abstract available.
-
BCG: a vaccine with multiple faces.Hum Vaccin Immunother. 2020 Aug 2;16(8):1841-1850. doi: 10.1080/21645515.2019.1706930. Epub 2020 Jan 29. Hum Vaccin Immunother. 2020. PMID: 31995448 Free PMC article. Review.
-
Expanded Scope of Bacillus Calmette-Guerin (BCG) Vaccine Applicability in Disease Prophylaxis, Diagnostics, and Immunotherapeutics.Infect Microbes Dis. 2020 Oct 20;2(4):144-150. doi: 10.1097/IM9.0000000000000040. eCollection 2020 Dec. Infect Microbes Dis. 2020. PMID: 38630099 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical